Abstract
BackgroundVarious studies have evaluated the significance of phosphohistone-H3 (PHH3) expression in cancer patients, but controversy over its reliability remains. We conducted a meta-analysis to summarize the prognostic relevance of PHH3 expression in cancer patients.Patients and methodsNineteen studies, including 4803 patients, were identified by searching PubMed, Web of Science, Embase, and Cochrane Library. The correlation of PHH3 expression level with overall survival (OS), disease-free survival, and recurrence-free survival was analyzed.ResultsOverall, the results suggest that high expression of PHH3 can predict a poor OS (HR=2.66, 95% CI=1.74–4.08, P<0.001), disease-free survival (HR=3.40, 95% CI=1.47–7.87, P=0.004), and recurrence-free survival (HR=2.80, 95% CI=1.61–4.85, P<0.001) in cancer patients. The subgroup analysis showed that highly expressed PHH3 was significantly related to breast cancer (HR=5.66, 95% CI=2.72–11.78, P<0.001) and urogenital tumors (HR=3.01, 95% CI=1.78–5.09, P<0.001). Furthermore, no significant difference was found between Asian (HR=1.98, 95% CI=1.08–3.63, P=0.026) and Caucasian populations (HR=3.01, 95% CI=1.87–4.85, P<0.001) regarding OS and PHH3 expression.ConclusionThis meta-analysis indicates that high expression of PHH3 may serve as a biomarker for poor prognosis in patients with cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
